Olympia Diagnostics, Inc.
Olympia Diagnostics is an In Vitro Diagnostics (IVD) company focusing on development and commercialization of the most advanced breakthrough products for cancer diagnosis and prognosis. We developed a proprietary biomarker discovery platform to identify and validate biomarkers important for cancer tumorigenesis, progression and metastasis. We developed biomarker-panels that are able to detect and diagnosis cancer, distinguish aggressive and non-aggressive cancer, distinguish metastatic and non-metastatic cancer, and predict cancer recurrence and patient survival, with very high sensitivity and specificity. We have developed four novel products for prostate cancer diagnosis and prognosis that can accurately diagnose prostate cancer and give treatment guidance.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Monitoring
- Market Focus:
- Nationally (across the country)
Our Mission
We strive to create the most accurate and actionable diagnostic and prognostic products to improve cancer detection, diagnosis and treatment. We are dedicated to saving people’s lives, reducing patient suffering, lowering healthcare cost and burden to the society.
Our Vision
We believe the current cancer diagnostic and prognostic tests are not ideal and there is an urgent need for improvement: they have low sensitivity/specificity and/or are invasive and costly. Many cancer patients are not detected by current diagnostic methods due to low sensitivity, therefore missed the opportunity to be treated early, which leads to mortality and cancer as the leading cause of death. On the other hand, many people without cancer had to endure invasive and repetitive tests due to low specificity of the current tests. Without accurate prognostic test to distinguish patients with aggressive, recurrent or metastatic cancer, many patients have to endure unnecessary treatment and suffering while patients with aggressive or recurrent cancer do not receive sufficient treatment that result in cancer progression, recurrence, metastasis and death. Therefore it is imperative to develop more accurate cancer diagnostic and prognostic tests.
Our Technology
We developed a proprietary biomarker discovery platform to identify and validate biomarkers important for cancer tumorigenesis, progression and metastasis. We developed biomarker-panels that are able to detect and diagnosis cancer, distinguish aggressive and non-aggressive cancer, distinguish metastatic and non-metastatic cancer, and predict cancer recurrence and patient survival, with very high sensitivity and specificity. Based on these biomarker-panels, we have developed test products that can accurately and quantitatively measure gene expression levels of the biomarkers in the panels using Real-Time quantitative PCR (Real-Time qRT-PCR) technology. Our proprietary algorithm is then used to give diagnosis or prognosis based on gene expression levels of a patient’s biomarker-panel.
Our Products
We have developed four novel products for prostate cancer diagnosis and prognosis that can accurately diagnose prostate cancer and give treatment guidance. Our products can distinguish prostate cancer from normal or benign prostate lesion, distinguish aggressive prostate cancer that requires immediate treatment from indolent prostate cancer that needs only surveillance, distinguish patients with metastatic cancer or will develop metastatic cancer from patients without metastatic cancer, distinguish patients who will have cancer recurrence from patients who will not, and predict patient survival time.
Our Dream
Our dream is to help patients and make a difference in their lives. By providing accurate and actionable diagnosis and prognosis for cancer detection, patient stratification, treatment guidance, and progression monitoring, we will be able to improve cancer detection and clinical treatment, avoid unnecessary suffering and save patient lives.
For Patients
About Prostate Cancer Diagnosis and Prognosis
Prostate cancer is one of the most prevalent cancers in men worldwide. Millions of men are diagnosed with prostate cancer and many of them died of it.
Prostate cancer is also a slow-growing cancer. For many men, the cancer is low-risk and remains indolent so they do not need treatment and only requires “watchful wait”. However, some men with prostate cancer that is high-risk and aggressive would need immediate treatment. Some men received prostatectomy or other treatments are “cured” of the disease, yet others’ cancer will come back and become metastatic and lethal.
Therefore it is not only important to detect and diagnose prostate cancer before the cancer becomes lethal and kill the patients, but also very important to tell if the cancer is high or low-risk, if the cancer has or will metastasize, if the cancer will recur, and if the patient can survive for long time.
Current Prostate Cancer Diagnostic and Prognostic Methods
To make correct diagnosis of prostate cancer and give good guidance to clinical treatment, we need accurate prostate cancer diagnostic and prognostic tests. However, currently no ideal and accurate prostate cancer diagnostic or prognostic test is available. No clinical or pathological parameter, no biomarker or panel of biomarkers has sufficiently high sensitivity and specificity that is able to give accurate cancer diagnosis or provide accurate and actionable clinical guidance to cancer treatment.
As a result of low sensitivity of current cancer diagnostic tests, many prostate cancer patients were not detected by current diagnostic methods, therefore missed the opportunity to be treated early, which led to patient death and prostate cancer as the second leading cause of cancer-related death. On the other hand, many men without cancer had to endure invasive and repetitive biopsies due to the low specificity of the current testing methods. Without accurate prognostic test, many low-risk and indolent prostate cancer patients had to endure unnecessary treatment including prostatectomy, radiation therapy and chemotherapy, while patients with high-risk and aggressive prostate cancer did not receive sufficient treatment which result in cancer recurrence, progression, metastasis and patient death.
Our Solutions for Patient Needs
Because of patients’ urgent need for more accurate prostate cancer diagnostic and prognostic tests, we set out to identify and develop novel and more accurate methods to address problems of existing tests.
After years of research and clinical development, we have successfully created four products that have much higher sensitivity and specificity than existing tests for prostate cancer diagnosis and prognosis. They are able to distinguish prostate cancer from normal or benign prostate lesion, to distinguish high-risk and aggressive prostate cancer that requires immediate treatment from low-risk and indolent prostate cancer that needs only surveillance, to distinguish patients with metastatic cancer or will develop metastatic cancer from patients without metastatic cancer, to distinguish patients who will have cancer recurrence from patients who will not, and predict patient survival time.
These tests will be used for cancer detection, patient stratification, treatment guidance, and cancer progression and recurrence monitoring. By using accurate diagnosis and prognosis, current problems of “false-negative” and “false-positive” in prostate cancer diagnosis, and “under-treatment” and “over-treatment” in clinical practice can be resolved, thus will significantly reduce cancer recurrence, metastasis and patient death. Ultimately this will greatly help patients by improving cancer treatment outcome, avoiding unnecessary patient suffering and lowering healthcare cost, and releasing burden to patient families and the society.
For Medical Professionals
Importance of Prostate Cancer Diagnosis and Prognosis
Biomarkers have great potential to improve cancer diagnosis and treatment. However, despite progress in new technology development (such as genomics, proteomics, metabolomics, next-generation sequencing, etc.) and tremendous resources and efforts being devoted to cancer biomarker research with publications of many thousands of biomarker discoveries, few clinically useful cancer diagnostic or prognostic biomarkers have been successfully developed and validated.
Prostate cancer is the second most common cancer in men and the second leading cause of cancer-related death in men.
Accurate prostate cancer screening and diagnostic tests have tremendous clinical benefit:
- No “false-negative” diagnosis and “under-treatment” resulted from low sensitivity of current tests: find and treat prostate cancer before it becomes aggressive and lethal
- Outcome: ~100% cure rate, avoid tumor recurrence, metastasis and mortality
- No “false-positive” diagnosis and “over-treatment” resulted from low specificity of current tests: non cancer patients do not get mis-diagnosed or treated; low-risk and indolent prostate cancer only needs surveillance
- Outcome: Avoid unnecessary treatment, surgery and patient suffering, greatly reduce healthcare cost
Accurate prostate cancer prognostic tests have tremendous clinical benefit:
- Metastatic cancer prognostics: identify patients who have or will develop metastatic prostate cancer so patients will receive most suitable treatment
- Cancer recurrence prognostics: identify patients who will or will not have cancer recurrence so patients will receive most suitable treatment based on cancer recurrence potential
- Survival prognostics: predict patient survival time so patients will receive most suitable treatment based on their survival prediction
- These prognostic tests provide personal medicine guidance on prostate cancer treatment: avoid both “under-treatment” and “over-treatment”
- Outcome: Increase cancer remission, reduce patient suffering and mortality, and lower healthcare cost.
Shortcomings of Current Prostate Cancer Diagnostic and Prognostic Methods
Currently no accurate and ideal prostate cancer diagnostic or prognostic test is available to give accurate cancer diagnosis or provide accurate and actionable clinical guidance to cancer treatment. No test has high sensitivity (>90%), high specificity (>90%) and high AUC (>0.9):
- Biopsy: invasive and expensive; low specificity: high rate of false negative so negative biopsy needs to be repeated for accurate diagnosis; cannot be used for cancer screening or prognosis
- Existing biomarkers such as PSA test: all have low sensitivity/specificity to give accurate diagnosis or prognosis
- Clinical or pathological parameters (such as age, Gleason score, cancer staging): all have low sensitivity/specificity to give accurate prognosis
Prostate cancer is a slow-growing and heterogeneous cancer. At molecular level, it consists of many subtypes of prostate cancer. Many gene alterations contribute to prostate cancer tumorigenesis and metastasis. Therefore no single biomarker, clinical or pathological parameter can provide accurate diagnosis or prognosis.
As a result of low sensitivity of current prostate cancer diagnostic tests, many patients were not detected by current diagnostic methods, therefore missed the opportunity to be treated early, which leads to mortality and prostate cancer as the second leading cause of cancer-related death. On the other hand, many men without cancer had to endure invasive and repetitive biopsies due to the low specificity of the current testing methods. Without accurate prognostic test, many indolent prostate cancer patients had to endure unnecessary treatment including surgery, radiation therapy and chemotherapy while patients with aggressive prostate cancer did not receive sufficient treatment that result in cancer recurrence, progression, metastasis and mortality.
Advantages of Our Products
- High accuracy: higher sensitivity and specificity than existing tests
- Clinical benefit: provide actionable guidance to cancer treatment
- Quantitative measurement: assessing expression levels of multiple biomarkers involved in prostate cancer
- Non-invasive: only need patient urine sample or biopsy tissue sample already taken from patient
- Easy procedure: test is easy to run, only needs real time PCR machine, can be done by most clinical labs
- Fast result: test result is available within the same day
- Inexpensive: cheaper than many existing test methods by testing multiple genes at the same time with multiplex PCR technology
Clinical Validation
Our products have been validated by multiple retrospective clinical studies with consistently high sensitivity and specificity. Currently we are conducting a prospective, multi-center clinical trial to further validate the products.
Partnerships
Clinical Partnership
Clinical development and clinical studies are essential to validation of our products. We are fortunate to have formed collaborations with many prominent and compassionate oncologists and urologists to conduct high quality clinical studies on our four products.
We constantly seek to collaborate with more top oncologists and clinicians worldwide to conduct more clinical studies on our four prostate cancer test products and our other tests being developed for diagnosis and prognosis of cervical, breast, ovarian, oral and bladder cancers.
Together we can help advance medicine and improve patient’s lives!
Research Partnership
We believe in the significant roles of scientific research and progress in translation of discoveries into medical advancement and better patient care. We use innovative research to create solutions for solving clinical problems.
We are collaborating with cancer biologists and medical scientists to conduct basic and translational research. We constantly seek to collaborate with more top scientists and clinicians worldwide to study and validate our current cancer test products and new tests being developed.
Together we can help advance science and medicine!
Business Partnership
We seek to collaborate with IVD companies, pharmaceutical companies, diagnostic labs and clinical testing labs to bring our break-through products to worldwide patients in need of accurate cancer diagnosis and prognosis.